Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary

Core Insights - Helius Medical Technologies, Inc. has established a wholly-owned subsidiary, Revelation Neuro, Inc., to develop non-implantable AI-powered brain-computer interface (BCI) technology aimed at improving neurorehabilitation [1][2][3] - The new technology will utilize Helius' existing intellectual property (IP) and a dataset of over 5 years of clinical evidence from more than 400 subjects to optimize therapeutic responses [3] - Helius plans to present at the 37th Annual Roth Conference on March 17, 2025, to discuss its advancements and future plans [4] Company Overview - Helius Medical Technologies focuses on neurologic deficits through a novel therapeutic neuromodulation approach, with its first commercial product being the Portable Neuromodulation Stimulator (PoNS) [5] - The company has invested over $70 million in developing its proprietary neuromodulation mechanism and data gathering, which will support the rapid development of Revelation Neuro's AI-powered BCI [3] Technology Development - Revelation Neuro aims to create a new standard of care for personalized neurorehabilitation by combining newly developed IP with Helius' existing IP, utilizing translingual stimulation to modulate brain processes without the need for implantation [2][3] - The focus will initially be on functional rehabilitation, with future potential applications in addressing cognitive deficits and mood disorders [3]